Lymphoedema risk assessment and referral

Practice Point

Lymphoedema risk assessment and referral

Patients at higher risk of lymphoedema (e.g. those in whom axillary clearance or axillary radiation therapy is planned, or patients with lymphatic insufficiency) should be referred to a lymphoedema therapist for assessment prior to breast cancer treatment, and for regular monitoring after breast cancer treatment. Bioimpedance measurements may be part of the clinical assessment.

How this guidance was developed

This practice point was developed using an expert consensus process. The practice point was informed by two source recommendations, one from the KCE 2013 guidelines (Belgium) that was graded ‘Strong’ using GRADE methods by the source guideline authors, and one from NICE 2018 guidelines (evidence review to 2007, not updated in 2017) that used wording ('Ensure') indicative of a strong recommendation.  The practice point was also informed by the principles of lymphoedema identification and management from the NSW Health, Agency for Clinical Innovation (2018).

Lymphoedema risk assessment and referral

Practice Point

Patients at higher risk of lymphoedema (e.g. those in whom axillary clearance or axillary radiation therapy is planned, or patients with lymphatic insufficiency) should be referred to a lymphoedema therapist for assessment prior to breast cancer treatment, and for regular monitoring after breast cancer treatment. Bioimpedance measurements may be part of the clinical assessment.

Principles in action
Image
Patient-centred care
Image
Supportive care

This practice point was developed using an expert consensus process. The practice point was informed by two source recommendations, one from the KCE 2013 guidelines (Belgium) that was graded ‘Strong’ using GRADE methods by the source guideline authors, and one from NICE 2018 guidelines (evidence review to 2007, not updated in 2017) that used wording ('Ensure') indicative of a strong recommendation.  The practice point was also informed by the principles of lymphoedema identification and management from the NSW Health, Agency for Clinical Innovation (2018).